In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two poster presentations highlighting data on CD388 at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference, being held A...
Heartland Financial USA, Inc. (“HTLF”) Announces Common Stock and Series E Preferred Stock Dividends DENVER, April 25, 2024 (GLOBE NEWSWIRE) -- Common Stock Dividend Heartland Financial USA, Inc. (NASDAQ: HTLF), operating under the brand name HTLF, announced its Board of Directors approved a quarterly cash dividend on common stock of $0.30 per share. The dividend is payable on May 28, 2024, to stockholders of record at the close of business on May 13, 2024. HTLF has increased or maintained its common stock dividend every quarter for more than 40 years. Series E Preferred Stock Divid...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Garrett Motion Reports First Quarter 2024 Financial Results First Quarter 2024 Highlights Net sales totaled $915 million, down 6% on a reported basis and 5% at constant currency*Net income totaled $66 million; Net income margin 7.2%Adjusted EBITDA* totaled $151 million; Adjusted EBITDA margin* of 16.5%Net cash provided by operating activities totaled $84 millionAdjusted free cash flow* totaled $68 millionRepurchased $109 million of Common Stock Reiterated Full Year 2024 Outlook Net sales of $3,870 million, flat on a reported and constant currency basis*Net income of $253 million; Net inc...
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer. Dr. Teel currently serves as Arvinas’ interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief Executive Officer, John Houston,...
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million - $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET ...
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an additional approximately $61 million in forecasted obligations through the patent life of rezafungin Cidara to further focus on advancing Cloudbreak development programs, including a planned IND filing for its lead oncology candidate, CBO421, as well a...
Virtu Announces First Quarter 2024 Results NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NASDAQ: VIRT), a leading provider of financial services and products that leverages cutting edge technology to deliver innovative, transparent trading solutions to its clients and liquidity to the global markets, today reported results for the first quarter ended March 31, 2024. First Quarter 2024: Net income of $111.3 million; Normalized Adjusted Net Income¹ of $124.3 millionBasic and diluted earnings per share of $0.59; Normalized Adjusted EPS¹ of $0.76Total revenues of $642....
Peapack-Gladstone Financial Corporation Reports First Quarter Results BEDMINSTER, NJ, April 23, 2024 (GLOBE NEWSWIRE) -- via -- Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market: PGC) (the “Company”) announces its first quarter 2024 financial results. This earnings release should be read in conjunction with the Company’s Q1 2024 Investor Update, a copy of which is available on our website at and via a current report on Form 8-K on the website of the Securities and Exchange Commission at . The Company recorded total revenue of $53.1 million, net income of $8.6 ...
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its corporate activities and product pipeline. “...
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that its failure to timely file its Annual Report o...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.